Log in to your Inderes Free account to see all free content on this page.
Orion
53.95
EUR
+0.75 %
13,982 following
ORNBV
NASDAQ Helsinki
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+0.75%
-5.12%
+6.28%
+26.11%
+15.48%
+62.99%
+32.52%
+14.3%
+380.41%
Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.
Read moreMarket cap
7.61B EUR
Turnover
3.84M EUR
P/E (adj.) (25e)
EV/EBIT (adj.) (25e)
P/B (25e)
EV/S (25e)
Dividend yield-% (25e)
Revenue and EBIT-%
Revenue B
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
18.7.
2025
Interim report Q2'25
15.10.
2025
Half year dividend
28.10.
2025
Interim report Q3'25
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types
Composition of the Nomination Committee of Orion Corporation
Orion, Webcast with teleconference, Q1'25
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
